DK1361884T3 - Sensibilisering af neoplastiske celler, der er resistente over for kemoterapeutisk middel, med reovirus - Google Patents

Sensibilisering af neoplastiske celler, der er resistente over for kemoterapeutisk middel, med reovirus

Info

Publication number
DK1361884T3
DK1361884T3 DK02701122.0T DK02701122T DK1361884T3 DK 1361884 T3 DK1361884 T3 DK 1361884T3 DK 02701122 T DK02701122 T DK 02701122T DK 1361884 T3 DK1361884 T3 DK 1361884T3
Authority
DK
Denmark
Prior art keywords
neovlastic
reovirus
sensitization
chemotherapeutic agent
cells resistant
Prior art date
Application number
DK02701122.0T
Other languages
English (en)
Inventor
Matthew C Coffey
Bradley G Thompson
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Application granted granted Critical
Publication of DK1361884T3 publication Critical patent/DK1361884T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK02701122.0T 2001-02-20 2002-02-19 Sensibilisering af neoplastiske celler, der er resistente over for kemoterapeutisk middel, med reovirus DK1361884T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27036301P 2001-02-20 2001-02-20
PCT/CA2002/000201 WO2002066040A2 (en) 2001-02-20 2002-02-19 Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus

Publications (1)

Publication Number Publication Date
DK1361884T3 true DK1361884T3 (da) 2011-10-03

Family

ID=23031034

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02701122.0T DK1361884T3 (da) 2001-02-20 2002-02-19 Sensibilisering af neoplastiske celler, der er resistente over for kemoterapeutisk middel, med reovirus

Country Status (16)

Country Link
US (5) US7264798B2 (da)
EP (2) EP1361884B1 (da)
JP (3) JP4951194B2 (da)
AR (1) AR035227A1 (da)
AT (1) ATE516807T1 (da)
AU (2) AU2002234453B2 (da)
BR (1) BR0207691A (da)
CA (1) CA2437468C (da)
DK (1) DK1361884T3 (da)
ES (1) ES2367768T3 (da)
HK (1) HK1060520A1 (da)
IL (2) IL157167A0 (da)
MX (1) MXPA03007486A (da)
NZ (2) NZ527399A (da)
WO (1) WO2002066040A2 (da)
ZA (1) ZA200305875B (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
JP4546823B2 (ja) * 2002-05-10 2010-09-22 オンコリティクス バイオテク，インコーポレーテッド 腫瘍崩壊性ウイルスによる放射線療法に対する新生物細胞の感作
MXPA05011462A (es) * 2003-04-25 2005-12-15 Wellstat Biologics Corp Tratamiento de carcinomas hepatocelulares utilizando virus terapeuticos.
CN100562570C (zh) 2003-06-18 2009-11-25 吉恩勒克斯公司 修饰的重组痘苗病毒及其它微生物,及其应用
JP5170741B2 (ja) 2004-04-27 2013-03-27 ウェルスタット バイオロジクス コーポレイション ウイルスおよびカンプトテシン類を使用する癌の処置
WO2005112966A1 (en) * 2004-05-21 2005-12-01 Orison Biotechnology Inc. Combined therapy with a herbal extract and a reovirus for killing neoplastic cells in a subject
RU2435586C2 (ru) * 2005-07-14 2011-12-10 Веллстат Байолоджикс Корпорейшн Лечение рака с применением вирусов, фторпиримидинов и камптотецинов
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
WO2007099401A2 (en) * 2005-08-01 2007-09-07 University Technologies International, Inc. Oncolytic attenuated reoviruses for treatment of proliferative disorders
EP1951274B1 (en) * 2005-11-24 2009-12-02 AiCuris GmbH & Co. KG Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer
WO2008100292A2 (en) 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
US20090081639A1 (en) * 2007-05-31 2009-03-26 Phil Hill Assay for sensitivity to chemotherapeutic agents
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
US20090162288A1 (en) * 2007-07-18 2009-06-25 Nanhai Chen Use of modified vaccinia virus strains in combination with a chemotherapeutic agent for use in therapeutic methods
MX2010003556A (es) * 2007-10-22 2010-04-21 Oncolytics Biotech Inc Regimen de tratamiento para trastornos proliferantes.
JP2011511072A (ja) * 2008-02-08 2011-04-07 ポニアード ファーマシューティカルズ， インコーポレイテッド 結腸直腸癌を治療するためのピコプラチンおよびベバシツマブの使用
EP2300023A2 (en) * 2008-05-16 2011-03-30 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
WO2009143468A1 (en) * 2008-05-22 2009-11-26 Uti Limited Partnership Tumor suppressor-based susceptibility of hyperproliferative cells to oncolytic viral therapy
MX2010012857A (es) * 2008-05-27 2010-12-20 Oncolytics Biotech Inc Supresion de produccion de citoquina proinflamatoria durante la terapia de reovirus oncolitico.
EP2296678A4 (en) * 2008-05-27 2012-03-21 Oncolytics Biotech Inc MODULATION OF INTERSTITIAL PRESSURE AND ONCOLYTIC VIRUS RELIEF AND DISTRIBUTION
AU2013204555A1 (en) * 2012-04-30 2013-11-14 Oncolytics Biotech Inc. Protecting modified viruses from neutralizing antibodies using the reovirus sigma 1 protein
EP3209382B1 (en) 2014-10-24 2020-11-25 Calidi Biotherapeutics, Inc. Combination immunotherapy approach for treatment of cancer
CN104881181B (zh) * 2015-05-27 2019-07-26 联想(北京)有限公司 显示方法及电子设备
JP7329593B2 (ja) 2018-11-06 2023-08-18 カリディ・バイオセラピューティクス・インコーポレイテッド 細胞媒介性腫瘍溶解性ウイルス治療のための増強された系

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT931830E (pt) 1993-02-16 2001-08-30 Onyx Pharma Inc Virus citopaticos para terapia e profilaxia de neoplasia
DK1486211T3 (da) 1993-04-30 2009-01-19 Wellstat Biologics Corp Sammensætninger til behandling af cancer ved anvendelse af vira
US5776743A (en) 1994-09-06 1998-07-07 La Jolla Cancer Research Foundation Method of sensitizing tumor cells with adenovirus E1A
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
AU9603898A (en) 1997-10-09 1999-05-03 Pro-Virus, Inc. Treatment of neoplasms with viruses
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
CA2720361A1 (en) * 1999-11-12 2001-05-25 Oncolytics Biotech, Inc. Viruses for the treatment of cellular proliferative disorders
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders

Also Published As

Publication number Publication date
ZA200305875B (en) 2004-07-30
IL157167A (en) 2014-05-28
US7964187B2 (en) 2011-06-21
ATE516807T1 (de) 2011-08-15
US8658158B2 (en) 2014-02-25
EP1361884A2 (en) 2003-11-19
EP2314301A3 (en) 2011-08-17
HK1060520A1 (en) 2004-08-13
WO2002066040A8 (en) 2003-03-20
US20020168344A1 (en) 2002-11-14
WO2002066040A2 (en) 2002-08-29
US20080031851A1 (en) 2008-02-07
ES2367768T3 (es) 2011-11-08
JP2012072192A (ja) 2012-04-12
AU2007207860B2 (en) 2008-10-23
US7264798B2 (en) 2007-09-04
US20130017172A1 (en) 2013-01-17
US20110243890A1 (en) 2011-10-06
BR0207691A (pt) 2006-01-31
CA2437468A1 (en) 2002-08-29
CA2437468C (en) 2007-06-19
JP4951194B2 (ja) 2012-06-13
WO2002066040A3 (en) 2003-05-30
AU2007207860A1 (en) 2007-09-06
AR035227A1 (es) 2004-05-05
EP1361884B1 (en) 2011-07-20
NZ537709A (en) 2006-11-30
US7608257B2 (en) 2009-10-27
AU2002234453B2 (en) 2007-05-17
MXPA03007486A (es) 2003-12-08
JP2008120837A (ja) 2008-05-29
NZ527399A (en) 2005-09-30
EP2314301A2 (en) 2011-04-27
IL157167A0 (en) 2004-02-08
US20100021432A1 (en) 2010-01-28
JP2004517966A (ja) 2004-06-17

Similar Documents

Publication Publication Date Title
DK1361884T3 (da) Sensibilisering af neoplastiske celler, der er resistente over for kemoterapeutisk middel, med reovirus
LU93311I2 (fr) Mancozèbe, valifenalate
DK1386921T3 (da) Mellemprodukter til fremstilling af anti-trombotiske 4H-cycolopenta-1,3-dioxol-derivater
DK1147114T3 (da) Hidtil ukendt aralkylaminer af spirofuropyridiner, der er egnede til terapi
DK1622619T3 (da) Kombinationer til behandling af sygedomme, som involverer celleproliferation, migration eller apoptose af myelomaceller, eller angiogenese
DK1438306T3 (da) Derivater af UK-2A
LTC1436271I2 (lt) Fenilpiperazino dariniai, kaip serotonino grįžtamos absorbcijos inhibitoriai
DK1453512T3 (da) Acetylenderivater med mGluR5 antagonistisk virkning
DK1580216T3 (da) Derivater med høj molekylvægt af camptotheciner
NO20033607L (no) Sementslurry med svaert lav tetthet
DK1156813T3 (da) Reovirus til behandling af cellulære proliferative lidelser
DE60318769D1 (de) Maskenüberzug
DK1720837T3 (da) Derivater af N-'(1,5-diphenyl-1H-pyrazol-3-yl)methylsulphonamid med CB1-receptoraffinitet
NO20013463L (no) <omega>-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
DK1339679T3 (da) 3-Aroylindolderivater og deres anvendelse som agonister af CB2-receptorer
DE60206616D1 (de) Trizyclische alkylhydroxamate, ihre herstellung und ihre verwendung als inhibitoren der zellproliferation
DK1212320T3 (da) Phenylpiperazinderivater som inhibitorer for genoptag af serotonin
NO20052663D0 (no) Partikkel med langstrakt form, anvendelse derav som en katalysator eller baerer
DK1827427T3 (da) Aryloxyethylaminderivater med en kombination af partiel dopamin-D2 receptoragonisme og inhibition af genoptag af serotonin
DK1600441T3 (da) Krystallinsk form af elrcanidipinhydrochlorid til anvendelse som et antihypertensivt middel
DK1144425T3 (da) Derivater af monosaccharider som celleadhæsionsinhibitorer
DK1499729T5 (da) Derivater af det NF-kappab-inducerende enzym, fremstilling og anvendelse deraf
ATE396994T1 (de) 3-phenylpyridoindolderivate, ihre herstellung und verwendung
DK1515990T3 (da) Antagonister af CXCR3-bindende CXC chemokiner
DE60309977D1 (de) Korrekturschaltung, Verzögerungsschaltung und Ringoszillator